For decades, concerns have been raised about the clinical trials enterprise in the US, from their high costs and lengthy time courses to their narrowness in scope and lack of representativeness. At the onset of the COVID-19 pandemic, coordinated testing and evaluation was at a premium. Although clinical trial research networks were quickly established in the UK, Australia, and elsewhere, any success at doing the same in the US seemed unlikely.
Source: JAMA Online First